Glitazones and the management of insulin resistance: what they do and how might they be used
- 1 September 2004
- journal article
- review article
- Published by Elsevier in Endocrinology and Metabolism Clinics of North America
- Vol. 33 (3) , 595-616
- https://doi.org/10.1016/j.ecl.2004.04.003
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndromeFertility and Sterility, 2004
- Regulation of Plasma PAI-1 Concentrations in HAART-Associated Lipodystrophy During Rosiglitazone TherapyArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 DiabetesDiabetes Care, 2002
- Control of Vascular Cell Proliferation and Migration by PPAR-γDiabetes Care, 2001
- Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non–insulin dependent diabetes mellitusJournal of the American College of Cardiology, 2000
- Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patientsDiabetes, 1998
- Increase of lipoprotein (a) with troglitazoneThe Lancet, 1997
- Associations of HDL 2 and HDL 3 Subfractions With Ischemic Heart Disease in MenArteriosclerosis, Thrombosis, and Vascular Biology, 1997
- Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus.Journal of Clinical Investigation, 1995
- Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patientsDiabetes, 1994